Compounds > acevaltrate
Page last updated: 2024-12-06

acevaltrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

acevaltrate: RN given for (1S-(1alpha,6alpha,7beta,7aalpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65717
CHEMBL ID563350
CHEBI ID80704
SCHEMBL ID2110695
MeSH IDM0239940

Synonyms (36)

Synonym
butanoic acid, 3-(acetyloxy)-3-methyl-, 4-((acetyloxy)methyl)-6,7a-dihydro-1-(3-methyl-1-oxobutoxy)spiro(cyclopenta(c)pyran-7(1h),2'-oxiran)-6-yl ester, (1s-(1-alpha,6-alpha,7-beta,7a-alpha))-
acevaltrate
(acetyloxy)valepotriate
1,7a-dihydro-1,6-dihydroxyspiro(cyclopenta(c)pyran-7(6h), 2'-oxirane)-4-methanol 4-acetate 1(or 6)-isovalerate 6(or 1)-(3-hydroxy-3-methylbutyrate, acetate)
einecs 246-685-1
acevaltratum
acevaltratum [inn-latin]
acetoxyvaltrate
acevaltrat [german]
acevaltrato [inn-spanish]
4-acetoxymethyl-1,6,7,7a-tetrahydrocyclopenta(c)pyran-7-spiro-2'-oxiran-1,8-diyl 6-(beta-acetoxyisovalerat) 1-isovalerat oder 1-(beta-acetoxyisovalerat) 6-isovalerat
acetovaltrate
1,7a-dihydro-1,6-dihydroxyspiro(cyclopenta(c)pyran-7(6h),2-oxirane)-4-methanol 4-acetate 1(or 6)-isovalerate 6(or 1)-(3-hydroxy-3-methylbutyrate acetate
acevaltrate [inn]
[(1s,6s,7r,7as)-4-(acetyloxymethyl)-1-(3-methylbutanoyloxy)spiro[6,7a-dihydro-1h-cyclopenta[c]pyran-7,2'-oxirane]-6-yl] 3-acetyloxy-3-methylbutanoate
chebi:80704 ,
CHEMBL563350
25161-41-5
(7-amino-2-oxo-2h-chromen-4-yl)-acetic acid
acevaltrat
unii-s9mfk45gy9
acevaltrato
s9mfk45gy9 ,
AKOS015896737
acevaltrate [mart.]
butanoic acid, 3-(acetyloxy)-3-methyl-, (1s,2'r,6s,7as)-4-((acetyloxy)methyl)-6,7a-dihydro-1-(3-methyl-1-oxobutoxy)spiro(cyclopenta(c)pyran-7(1h),2'-oxiran)-6-yl ester
SCHEMBL2110695
HY-N2070
CS-0018575
DTXSID30179834
mfcd01741123
Q15633961
butanoic acid, 3-(acetyloxy)-3-methyl-, (1s,2'r,6s,7as)-4-[(acetyloxy)methyl]-6,7a-dihydro-1-(3-methyl-1-oxobutoxy)spiro[cyclopenta[c]pyran-7(1h),2'-oxiran]-6-yl ester
A877689
MS-28938
(1s,6s,7r,7as)-4-(acetoxymethyl)-1-((3-methylbutanoyl)oxy)-6,7a-dihydro-1h-spiro[cyclopenta[c]pyran-7,2'-oxiran]-6-yl 3-acetoxy-3-methylbutanoate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
fatty acid esterA carboxylic ester in which the carboxylic acid component can be any fatty acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID423379Cytotoxicity against human A549 cells after 24 hrs by MTT assay2009Journal of natural products, Apr, Volume: 72, Issue:4
Acylated iridoids with cytotoxicity from Valeriana jatamansi.
AID423381Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay2009Journal of natural products, Apr, Volume: 72, Issue:4
Acylated iridoids with cytotoxicity from Valeriana jatamansi.
AID423380Cytotoxicity against human HCT8 cells after 24 hrs by MTT assay2009Journal of natural products, Apr, Volume: 72, Issue:4
Acylated iridoids with cytotoxicity from Valeriana jatamansi.
AID423382Cytotoxicity against human PC3M cells after 24 hrs by MTT assay2009Journal of natural products, Apr, Volume: 72, Issue:4
Acylated iridoids with cytotoxicity from Valeriana jatamansi.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's5 (50.00)29.6817
2010's1 (10.00)24.3611
2020's3 (30.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.57 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.42 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
indoleacetic acid
indoleacetic acid: RN given refers to unlabeled parent cpd; structure in Merck Index, 9th ed, #4841. auxin : Any of a group of compounds, both naturally occurring and synthetic, that induce cell elongation in plant stems (from Greek alphaupsilonxialphanuomega, "to grow").. indole-3-acetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by a 1H-indol-3-yl group.		2.0210indole-3-acetic acids;
monocarboxylic acid		auxin;
human metabolite;
mouse metabolite;
plant hormone;
plant metabolite
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		1.98101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
1-naphthaleneacetic acid
1-naphthaleneacetic acid: a plant growth regulator; RN given refers to parent cpd. naphthylacetic acid : A monocarboxylic acid that is naphthalene substituted by a carboxymethyl group at any position.. 1-naphthaleneacetic acid : A naphthylacetic acid substituted by a carboxymethyl group at position 1.		2.0210naphthylacetic acidsynthetic auxin
indolebutyric acid
indolebutyric acid: RN given refers to parent cpd. indole-3-butyric acid : A indol-3-yl carboxylic acid that is butanoic acid carrying a 1H-indol-3-yl substituent at position 1.		2.0210indol-3-yl carboxylic acidauxin;
plant hormone;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0510taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
didrovaltrate
didrovaltrate: RN given refers to (1S-(1alpha,4aalpha,6alpha,7beta,7aalpha))-isomer		3.1150iridoid monoterpenoid
valtrate
valtrate: Baldrisedon contains 100mg extract of Radix Valerianae mexicanae which contains 50mg valepotriate		3.4270fatty acid ester
iridoids
Iridoids: A type of MONOTERPENES, derived from geraniol. They have the general form of cyclopentanopyran, but in some cases, one of the rings is broken as in the case of secoiridoid. They are different from the similarly named iridals (TRITERPENES).		3.6690
valmane
valtrates (combination): from Valerianaceae species; combination of valtratum, acevaltratum & didrovaltratum; structure (valtratum)		2.7230
cyclin d1
Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.		2.3110
ConditionIndicatedRelationship StrengthStudiesTrials
Astrocytoma, Grade IV
[description not available]		02.3110
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.3110
Kahler Disease
[description not available]		02.3110
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		02.3110
Drug Withdrawal Symptoms
[description not available]		01.9810
Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.		01.9810